Canaccord analyst Caitlin Cronin raised the firm’s price target on Smith & Nephew to $28 from $27 and keeps a Hold rating on the shares. The firm said they delivered a solid Q1 overall, slightly beating consensus and maintaining its guidance through the P&L. The company saw similar LSD reported growth across its portfolio segments as China headwinds which it believes have peaked, and one fewer selling day impacted growth as anticipated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Cautious Hold Rating on Smith & Nephew Amid Mixed Performance and Ambitious Targets
- Smith & Nephew Announces Successful AGM Resolutions
- Smith & Nephew Reports Strong Q1 2025 Growth Amid Challenges
- Smith & Nephew Reports Strong Start to 2025 with Revenue Growth
- Nuo Therapeutics enters Centrio distribution pact with Smith & Nephew